St. Jude Medical Announces European Launch Of Trifecta Tissue Valve

(RTTNews) - St. Jude Medical, Inc. (STJ) announced the European launch of the company's most advanced tissue valve, the Trifecta valve with Glide Technology, for the treatment of diseased, damaged or malfunctioning aortic heart valves, which control blood flow from the heart to the rest of the body. Trifecta GT tissue valve received CE Mark approval in February 2016.

Philip Ebeling, chief technology officer at St. Jude Medical, said: "The improved design of the Trifecta GT tissue valve allows for smoother placement while providing nearly unobstructed blood flow over the life of the valve."